US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

11.10

+0.57005.41%

Post-market: 11.07-0.0300-0.27%16:44 EDT

Volume:133.71K

Turnover:1.48M

Market Cap:546.65M

PE:-2.46

High:11.36

Open:10.62

Low:10.58

Close:10.53

52wk High:17.82

52wk Low:8.75

Shares:49.25M

Float Shares:13.84M

Volume Ratio:1.14

T/O Rate:0.97%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:5.22

PE(LYR):-0.07

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from H.C. Wainwright

Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB)

Agomab Therapeutics Director Naimish Patel Files Initial Beneficial Ownership Statement

Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/AGMB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":11.1,"timestamp":1790798400000,"preClose":10.53,"halted":0,"volume":133705,"hourTrading":{"tag":"盘后","latestPrice":11.07,"preClose":11.1,"latestTime":"16:44 EDT","volume":245,"amount":2719.45982,"timestamp":1790801064817,"change":-0.03,"changeRate":-0.002703,"amplitude":0.003604},"delay":0,"changeRate":0.05413105413105416,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Post-Mkt","change":0.57,"latestTime":"09-30 18:35:13 EDT","open":10.62,"high":11.36,"low":10.575,"amount":1483978.4245,"amplitude":0.074549,"askPrice":14.65,"askSize":100,"bidPrice":8.99,"bidSize":126,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":10.53,"preHourTrading":{"tag":"盘前","latestPrice":10.74,"preClose":10.53,"latestTime":"09:26 EDT","volume":143,"amount":1521.819871,"timestamp":1790774797189,"change":0.21,"changeRate":0.019943,"amplitude":0.018993},"postHourTrading":{"tag":"盘后","latestPrice":11.07,"preClose":11.1,"latestTime":"16:44 EDT","volume":245,"amount":2719.45982,"timestamp":1790801064817,"change":-0.03,"changeRate":-0.002703,"amplitude":0.003604},"volumeRatio":1.137849},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":1.137849,"shares":49248000,"dividePrice":0,"high":11.36,"amplitude":0.074549,"preClose":10.53,"low":10.575,"week52Low":8.75,"pbRate":"5.22","week52High":17.82,"institutionHeld":0,"latestPrice":11.1,"committee":0.115044,"eps":-4.51426,"divideRate":0,"volume":133705,"delay":0,"ttmEps":-4.51426,"open":10.62,"prevYearClose":16,"prevWeekClose":10.51,"prevMonthClose":13.17,"prevQuarterClose":12.98,"fiveDayClose":10.765,"twentyDayClose":13.54,"sixtyDayClose":13.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-09-29","current":-2.332608,"percent":0.99375,"low":-14.725744,"twenty":-11.13608,"median":-8.778373,"eighty":-7.639457,"high":-6.52172,"avg":-9.449837,"sd":2.190706,"marketCap":502821824},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-18","current":-7.774516,"twenty":-11.657926,"median":-8.880371,"eighty":-7.795572,"marketCap":594915538},{"date":"2026-09-25","current":-6.876368,"twenty":-11.321652,"median":-8.807045,"eighty":-7.758992,"marketCap":521043575},{"date":"2026-09-29","current":-6.657768,"twenty":-11.13608,"median":-8.778373,"eighty":-7.639457,"marketCap":502821824}],"updateTime":1790773144794},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669167777","title":"AgomAb Therapeutics NV ADR (AGMB) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167777?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:55","pubTimestamp":1790013335,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on AgomAb Therapeutics NV ADR, with a price target of $35...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/agomab-therapeutics-nv-adr-agmb-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DINT","DIVL","AGMB","ARMH","BK4007","APIE","CVY","SAPH","AADR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169130","title":"Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169130?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:50","pubTimestamp":1789998610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Charles River Labs (CRL) and AgomAb Therapeutics NV ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-charles-river-labs-crl-and-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-charles-river-labs-crl-and-agomab-therapeutics-nv-adr-agmb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","DINT","AGMB","APIE","SAPH","BK4585","LU0390134368.USD","LU0029874061.USD","IE00BFMHRM44.USD","HCSG","BK4137","CRL","LU1815336091.USD","CVY","XBI","AADR","BK4007","DIVL","ARMH","BK4121","BK4581","LU0757428866.USD","LABU","BK4588","BK4530","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667992624","title":"Agomab Therapeutics Director Naimish Patel Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2667992624","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667992624?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:06","pubTimestamp":1789502776,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics director Naimish Patel files initial beneficial ownership statementAgomab Therapeutics filed an initial Form 3 naming Naimish Patel as a director, marking his entry into SEC inside","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nNDL4gyF04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667957316","title":"Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667957316","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667957316?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:48","pubTimestamp":1789418880,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics said a phase 1 study for a lung disease treatment showed a reduction in a target protein, supporting the launch of a phase 2 study.The clinical-stage biopharmaceutical company said that a twice-daily 4.5mg dose of AGMB-447, a treatment for idiopathic pulmonary fibrosis, had a more than 50% reduction of pSMAD3 proteins in lung fluid cells.The dosage also had a generally favorable safety and tolerability profile, the company said. A 6mg twice-daily dose also evaluated in the study had a higher incidence of adverse events but no new specific safety signals.\"We believe that by blocking the TGF<BETA>/ALK5 pathway locally in the lung, AGMB-447 has the potential to offer a potent anti-fibrotic therapy to IPF patients,\" Chief Medical Officer Philippe Wiesel said. \"The extensive data collected in our broad Phase 1 program supports the initiation of our Phase 2 INSPIRIA study later this year.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":13,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AGMB\",params:#limit:6,delay:false,,,undefined,":[]}}